Springbok Analytics is a technology company.
Springbok Analytics has raised $5.0M across 1 funding round.
Springbok Analytics has raised $5.0M in total across 1 funding round.
Springbok Analytics has raised $5.0M in total across 1 funding round.
Springbok Analytics's investors include Bascom Ventures, TY.
Springbok Analytics is a life sciences technology company that develops AI-powered software to analyze 2D MRI scans into detailed 3D visualizations of individual muscle health, quantifying metrics like volume, fat infiltration, symmetry, and composition across over 100 muscles.[1][2][5][6] It serves life sciences researchers, clinicians, elite sports teams, and human performance professionals by solving the problem of inaccurate, outdated muscle assessment methods—replacing external estimates with precise, actionable, MRI-derived insights for injury prevention, recovery, rehabilitation, performance optimization, and disease treatment like FSHD.[1][2][3][5][6][7] The company, founded in 2013 and headquartered in Charlottesville, Virginia, has raised $7.3M total, including a $5M Series A round four months ago, and recently signed the New York Liberty as its first WNBA client while leading MRI analysis in a pediatric FSHD study.[1][2]
Springbok Analytics originated from over 15 years of academic research at the University of Virginia, where founders Silvia Blemker, Ph.D. (Biomedical Engineering), Joe Hart, Ph.D. (Kinesiology), and Craig Meyer, Ph.D. (Biomedical Engineering, Radiology & Medical Imaging) developed patented technology for precise MRI-based muscle assessment.[2][3] Initially created as a scientific research tool, the idea emerged to address limitations in measuring muscle health foundational to movement, performance, recovery, and aging.[3] Scott Magargee, JD, joined as CEO and co-founder in December 2019, bringing health tech commercialization expertise from early-stage ventures.[3] Early traction built through scientific validation, evolving into FDA-cleared commercial solutions with applications in sports and clinical studies, including pivotal partnerships like the recent WNBA deal and NIH-funded pediatric FSHD research.[1][7]
Springbok rides the convergence of AI in medical imaging and precision medicine, capitalizing on growing demand for objective musculoskeletal data amid rising chronic conditions like muscular dystrophy, sports injuries, and age-related decline.[1][3][7] Timing aligns with AI advancements enabling rapid, scalable analysis of complex MRI data, addressing gaps in traditional diagnostics amid expanding digital health markets—evident in its inclusion in CB Insights' AI and Digital Health collections.[1] Favorable forces include widespread MRI availability, NIH funding for studies like MOVE Peds FSHD trial, and pro sports adoption (e.g., first WNBA client), positioning Springbok to influence clinical trials, athlete performance, and personalized rehab.[1][7] By standardizing muscle health metrics, it enhances ecosystem-wide research efficiency and trial readiness for neuromuscular diseases.[7]
Springbok Analytics is poised for accelerated growth post-Series A, expanding from research tools to mainstream adoption in sports, pharma trials, and clinics, with recent wins like WNBA partnerships and FSHD studies signaling momentum.[1][7] Trends like AI-driven personalization in health tech and rising focus on preventive musculoskeletal analytics will propel it, potentially unlocking full-body scaling and integrations with wearables or telehealth. Its influence may evolve from niche innovator to ecosystem standard-setter, driving better outcomes in performance and disease management—transforming how we quantify what powers human potential, just as its MRI insights reveal hidden muscle realities.[3][5]
Springbok Analytics has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $5.0M Series A | Bascom Ventures, TY |